Mo1317 Health Plan Paid Costs and Drivers of Health Care Costs for Patients With Crohn's Disease Insured At Six Different Commercial Health Plans in the United States

2013 ◽  
Vol 144 (5) ◽  
pp. S-635 ◽  
Author(s):  
David T. Rubin ◽  
Richard B. Colletti ◽  
Bal K. Sharma ◽  
Amy Thompson ◽  
Andrew Krueger
Author(s):  
Grace Chen ◽  
Vasantha Pedarla ◽  
Kyle D Null ◽  
Susan E Cazzetta ◽  
Qasim Rana Khan ◽  
...  

Abstract Background Perianal fistula (PAF), a complication of Crohn’s disease (CD), is associated with substantial economic costs and poor prognosis. We determined prevalence of PAF CD in the United States and compared costs and health care resource utilization (HRU) of PAF CD patients with matched non-PAF CD patients. Methods This was a retrospective cohort study of claims data from the IBM MarketScan Commercial Database from October 1, 2015, to September 30, 2018. Eligible patients were aged 18 to 89 years with ≥2 CD diagnoses. Patients with PAF CD had ≥1 PAF diagnosis or procedure code and were matched with non-PAF CD patients. Cumulative prevalence of PAF CD in the US population was calculated across total patients in MarketScan. All-cause and gastrointestinal (GI)-related costs and HRU were compared between groups using a generalized linear model (GLM). Results Cumulative 3-year prevalence of PAF was 7.70% of patients with CD (N = 81,862) and 0.01% of the US population. Among PAF CD (n = 1218) and matched non-PAF CD (n = 4095) patients, most all-cause costs and HRU were GI-related. Mean total all-cause and GI-related health care costs per patient and per year for PAF CD were $85,233 and $71,612, respectively, vs $40,526 and $29,458 for non-PAF CD (P < .0001). Among PAF CD vs non-PAF CD patients, GLM-adjusted proportions of patients with GI-related inpatient, outpatient, or pharmacy visits, mean GI-related inpatient length of stay, and mean GI-related surgeries were higher (P < .0001 for all comparisons). Conclusions Costs and HRU are significantly higher for patients with PAF CD vs non-PAF CD patients, highlighting the economic burden of the disease.


2008 ◽  
Vol 135 (6) ◽  
pp. 1907-1913 ◽  
Author(s):  
Michael D. Kappelman ◽  
Sheryl L. Rifas–Shiman ◽  
Carol Q. Porter ◽  
Daniel A. Ollendorf ◽  
Robert S. Sandler ◽  
...  

Author(s):  
John F. Newman ◽  
William B. Elliott ◽  
James O. Gibbs ◽  
Helen C. Gift

2020 ◽  
Vol 174 (2) ◽  
pp. 200 ◽  
Author(s):  
Andrea E. Strahan ◽  
Gery P. Guy ◽  
Michele Bohm ◽  
Meghan Frey ◽  
Jean Y. Ko

2019 ◽  
Vol 25 (11) ◽  
pp. 1773-1779 ◽  
Author(s):  
David A Schwartz ◽  
Ignacio Tagarro ◽  
Mary Carmen Díez ◽  
William J Sandborn

Abstract Background Fistulas may arise as a relevant complication of Crohn’s disease (CD). Despite their clinical significance and the substantial burden imposed on patients, limited data are available on the epidemiology of fistulizing CD in the United States. Methods A systematic literature review was conducted to identify data published between 1970 and 2017 on the epidemiology of fistulas in patients with CD, with the aim to estimate the number of prevalent cases in the United States. Retrieved titles and abstracts were screened by 2 independent researchers for inclusion criteria (US population-based studies reporting data on the epidemiology of fistulizing CD). To validate the literature-based estimate, data from a US claims database (Truven Health MarketScan database) were analyzed. This database has broad geographic coverage, with health care data for >60 million patients during the period of the analysis. Results The literature search retrieved 7 articles for full-text review, and only 1 met the criteria for inclusion. This study described the cumulative incidence of fistulas in a CD population from Minnesota over 20 years. From the reported data, the estimated number of prevalent cases with fistulizing CD in the United States was ~76,600 in 2017 (~52,900 anal, ~7400 rectovaginal, ~2300 enterocutaneous, and ~14,100 internal). Analysis from the US health care database resulted in an estimated number of ~75,700 patients, confirming the robustness of the original estimate from the literature. Conclusions Based on 2 separate analyses, the estimated number of patients with fistulizing CD in the United States is ~77,000 patients.


1999 ◽  
Vol 89 (8) ◽  
pp. 1194-1199 ◽  
Author(s):  
D B Allison ◽  
R Zannolli ◽  
K M Narayan

Sign in / Sign up

Export Citation Format

Share Document